[Asia Economy Reporter Kwon Jaehee] LegoChem Bio announced on the 19th that it has signed an antibody technology licensing agreement with China's Harbour BioMed for new antibody-drug conjugate (ADC) research and development.
The contract amount was not disclosed.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
